Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relmada Therapeutics (RLMD) Retained Earnings (2016 - 2026)

Relmada Therapeutics has reported Retained Earnings over the past 3 years, most recently at $74655.0 for Q1 2014.

  • Quarterly Retained Earnings rose 394.99% to $74655.0 in Q1 2014 from the year-ago period, while the trailing twelve-month figure was $74655.0 through Feb 2014, up 394.99% year-over-year, with the annual reading at $57157.0 for FY2013, 370.74% up from the prior year.
  • Retained Earnings was $74655.0 for Q1 2014 at Relmada Therapeutics, up from $71531.0 in the prior quarter.
  • Over five years, Retained Earnings peaked at $74655.0 in Q1 2014 and troughed at -$25308.0 in Q1 2013.
  • The 3-year median for Retained Earnings is $50975.0 (2013), against an average of $39161.7.
  • Year-over-year, Retained Earnings soared 370.74% in 2013 and then skyrocketed 394.99% in 2014.
  • A 3-year view of Retained Earnings shows it stood at $12142.0 in 2012, then surged by 489.12% to $71531.0 in 2013, then increased by 4.37% to $74655.0 in 2014.
  • Per Business Quant, the three most recent readings for RLMD's Retained Earnings are $74655.0 (Q1 2014), $71531.0 (Q4 2013), and $57157.0 (Q3 2013).